MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$3,412K
Free Cash flow
-$4,364K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Stock-based compensation expense
    • Prepaid expenses
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Other current assets
    • Operating lease liability
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-5,000 -3,244 -15,402 -
Change in fair value of warrant liability
-0 0 -
Change in fair value of forward contract liability
-0 0 -
Commitment fee payable
--0 -
Other assets
-0 0 48
Payable to parent
-0 0 -
Change in fair value of sepa put option liability
54 329 23 -
Change in fair value of convertible debt
0 -810 -846 -117
Commitment fee expense
-0 --
Gain on termination of warrant and commitment fee liabilities
-0 --
Non-cash discount on convertible debt
-0 625 -
Stock-based compensation expense
694 702 704 1,280
Amortization of operating lease right-of-use asset
171 168 166 254
Depreciation expense
66 66 65 113
Prepaid expenses
-435 1,082 -960 1,108
Accounts payable and accrued expenses
-95 -124 -732 -646
Other current assets
403 0 0 -18
Operating lease liability
-178 -130 -170 -250
Net cash used in operating activities
-4,364 -3,163 -3,972 -9,259
Purchases of property and equipment
0 0 6 256
Net cash used in investing activities
0 0 -6 -256
Proceeds from short-term convertible debt
-4,375 --
Proceeds from short-term borrowing
--4,375 0 4,375
Repayments of short-term borrowing
-0 0 0
Proceeds from loan payable
327 ---
Repayments of short-term convertible debt
-3,400 --
Repayments of loan payable
81 ---
Proceeds from issuance of common stock, net of direct costs
706 6,590 0 0
Net cash provided by financing activities
952 3,190 0 4,375
Net decrease in cash and cash equivalents
-3,412 27 -3,978 -5,140
Cash and cash equivalents, beginning of period
4,894 4,867 13,985 -
Cash and cash equivalents, end of period
1,482 4,894 4,867 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock, net of...$706K Proceeds from loanpayable$327K Net cash provided byfinancing activities$952K Canceled cashflow$81K Net decrease in cashand cash...-$3,412K Canceled cashflow$952K Stock-based compensationexpense$694K Prepaid expenses-$435K Amortization of operatinglease right-of-use...$171K Depreciation expense$66K Repayments of loan payable$81K Net cash used inoperating activities-$4,364K Canceled cashflow$1,366K Net loss-$5,000K Other current assets$403K Operating lease liability-$178K Accounts payable andaccrued expenses-$95K Change in fair value ofsepa put option...$54K

FibroBiologics, Inc. (FBLG)

FibroBiologics, Inc. (FBLG)